Education
About Us
Working with TipRanks
Follow Us
Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
SANN Stock Chart & Stats
CHF13.88
-CHF0.14(-0.88%)
At close: 4:00 PM EST
CHF13.88
-CHF0.14(-0.88%)
Day’s Range― - ―
52-Week RangeCHF9.38 - CHF17.76
Previous CloseN/A
Volume24.19K
Average Volume (3M)55.85K
Market Cap
CHF184.55M
Enterprise ValueCHF210.76M
Total Cash (Recent Filing)CHF18.40M
Total Debt (Recent Filing)CHF76.30M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding14,565,505
10 Day Avg. Volume57,231
30 Day Avg. Volume55,851
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.68
Price to Sales (P/S)4.02
P/FCF Ratio-4.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF30.00Price Target Upside116.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety And Efficacy ProfileAnalyst highlights that AGAMREE (vamorolone) preserves motor function over extended follow-up while showing a safer tolerability profile with fewer vertebral fractures and maintained normal growth compared with traditional corticosteroids, enhancing its clinical differentiation.
European Commercial Rollout And Market AccessAnalyst observes accelerating direct sales in Germany, strong uptake in Austria and nationwide availability in the United Kingdom after positive guidance, with launches planned for the Nordic countries, Spain and Portugal and ongoing pricing discussions that can expand patient access.
Licensing And Regional PartnershipAnalyst notes the licensing agreement shifts development, manufacturing and commercialization duties to an experienced Asia-Pacific partner, lowering Santhera's operational risk and allowing focus on strategic priorities.
Bears Say
Santhera Pharmaceuticals Holding News
SANN FAQ
What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest stock price was CHF9.38 and its highest was CHF17.76 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is CHF184.55M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
Santhera Pharmaceuticals Holding’s upcoming earnings report date is Apr 23, 2026 which is in 98 days.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Santhera Pharmaceuticals Holding released its earnings results on Sep 23, 2025. The company reported -CHF3.04 earnings per share for the quarter, missing the consensus estimate of -CHF0.6 by -CHF2.44.
Is Santhera Pharmaceuticals Holding overvalued?
According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 14,565,505 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Santhera Pharmaceuticals Holding reported an EPS of -CHF3.04 in its last earnings report, missing expectations of -CHF0.6. Following the earnings report the stock price went down -14.141%.
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in CH:SANN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
SANN Company Deck
SANN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all CH:SANN earnings summariesSANN Stock 12 Month Forecast
Average Price Target
CHF30.00
▲(116.17% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---